TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Chimeric Therapeutics Ltd. ( (AU:CHM) ) is now available.
Chimeric Therapeutics announced promising results from its CHM CDH17 Phase 1/2 clinical trial, showing 75% disease control among evaluable subjects at 28 days. The trial, which focuses on advanced colorectal cancer, gastric cancer, and gastrointestinal NETs, demonstrated stable disease in all patients treated at Dose Level 2, with one patient maintaining stable disease for nearly a year without additional therapy. This progress underscores the potential impact of CHM CDH17 as a novel CAR-T cell therapy targeting CDH17, a biomarker linked to poor prognosis in gastrointestinal tumors.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics is an Australian clinical-stage company specializing in cell therapy, with a focus on developing innovative treatments for cancer. The company boasts a diversified portfolio that includes first-in-class autologous CAR T cell therapies and best-in-class allogeneic NK cell therapies, targeting various oncology areas through its four clinical-stage programs.
Technical Sentiment Signal: Sell
Current Market Cap: A$10.93M
See more data about CHM stock on TipRanks’ Stock Analysis page.